miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-κB signaling pathway

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 1, 2015, Pages 73-81

  Lan, Fengming ^a,b   Yue, Xiao ^c   Ren, Gang ^a   Li, Hongqi ^a   Ping, Li ^a   Wang, Yingjie ^a   Xia, Tingyi ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b Tianjin Hospital   (China)

^c Tianjin Huanhu Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; BIOINFORMATICS; BIOLOGICAL ORGANS; CELL DEATH; DISEASES; DRUG PRODUCTS; PIGMENTS; RADIATION; RADIOTHERAPY; RNA; SIGNALING; TUMORS;

BIOINFORMATIC ANALYSIS; LUCIFERASE REPORTER ASSAYS; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; RADIATION SENSITIVITY; RADIATION TREATMENTS; RADIATION-INDUCED APOPTOSIS; TOLL-LIKE RECEPTORS;

CELL SIGNALING;

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 15A; MICRORNA 16; TOLL LIKE RECEPTOR 1; 3' UNTRANSLATED REGION; LUCIFERASE; MICRORNA; MIRN15 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BIOCHEMICAL COMPOSITION; BIOINFORMATICS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; LUCIFERASE ASSAY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; 3' UNTRANSLATED REGION; ADENOCARCINOMA; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; DOWN REGULATION; DRUG SCREENING; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; MOUSE; NUDE MOUSE; PHYSIOLOGY; RADIATION DOSE; RADIATION RESPONSE; RANDOMIZATION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; HUMANS; LUCIFERASES; LUNG; LUNG NEOPLASMS; MICE; MICE, NUDE; MICRORNAS; NF-KAPPA B; RADIATION TOLERANCE; RANDOM ALLOCATION; TOLL-LIKE RECEPTOR 1; TUMOR STEM CELL ASSAY;

EID: 84923116116     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.09.021     Document Type: Article

References (33)

1. Kelsey CR, Jackson L, Langdon S, et al. A polymorphism within the promoter of the TGFbeta1 gene is associated with radiation sensitivity using an objective radiologic endpoint. Int J Radiat Oncol Biol Phys 2012;82:e247-e255.
2. Kauppila JH, Selander KS. Toll-like receptors in esophageal cancer. Front Immunol 2014;5:200.
3. Yang H, Wang B, Yan J, et al. Toll-like receptor 2 promotes invasion by SGC-7901 human gastric carcinoma cells and is associated with gastric carcinoma metastasis. Ann Clin Lab Sci 2014;44:158-166.
4. Weber AN, Forsti A. Toll-like receptor genetic variants and colorectal cancer. Oncoimmunology 2014;3:e27763.
5. Zhang YB, He FL, Fang M, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 2009;36:1475-1481.
6. Tye H, Kennedy CL, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012;22:466-478.
7. Guo H, Chen Y, Hu X, et al. The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells. Mol Cancer 2013;12:77.
8. Eiro N, Altadill A, Juarez LM, et al. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res 2014;44:769-778.
9. Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 2013;12: 1676-1687.
10. Voo KS, Foglietta M, Percivalle E, et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 2014;135:2834-2846 [Epub ahead of print].
11. Vacchelli E, Eggermont A, Sautes-Fridman C, et al. Trial watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013;2: e25238.
12. Galli R, Paone A, Fabbri M, et al. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARbeta and tumor regression. Proc Natl Acad Sci U S A 2013;110: 9812-9817.
13. Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011;30:4231-4242.
14. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ 2010; 17:215-220.
15. Chen F, Hou SK, Fan HJ, et al. MiR-15a-16 represses Cripto and inhibits NSCLC cell progression. Mol Cell Biochem 2014;391:11-19.
16. Grosso S, Doyen J, Parks SK, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 2013;4:e544.
17. Chen S, Wang H, Ng WL, et al. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys 2011;81:1524-1529.
18. Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009;69:5553-5559.
19. Zhang C, Kang C, Wang P, et al. MicroRNA-221 and -222 regulate radiation sensitivity by targeting the PTEN pathway. Int J Radiat Oncol Biol Phys 2011;80:240-248.
20. Balca-Silva J, Sousa Neves S, Goncalves AC, et al. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res 2012;32:1603-1609.
21. Josson S, Sung SY, Lao K, et al. Radiation modulation of microRNA in prostate cancer cell lines. Prostate 2008;68:1599-1606.
22. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007;67:11111-11116.
23. Yan D, Ng WL, Zhang X, et al. Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One 2010;5:e11397.
24. Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 2011;101:171-176.
25. Tergaonkar V, Pando M, Vafa O, et al. p53 stabilization is decreased upon NFkappaB activation: A role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
26. Janssens S, Tinel A, Lippens S, et al. PIDD mediates NF-kappaB activation in response to DNA damage. Cell 2005;123:1079-1092.
27. Rawat N, Alhamdani A, McAdam E, et al. Curcumin abrogates bileinduced NF-kappaB activity and DNA damage in vitro and suppresses NF-kappaB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett's oesophagus. Clin Transl Oncol 2012;14:302-311.
28. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002;21:6510-6519.
29. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805:167-180.
30. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001; 20:7342-7351.
31. Zhu L, Fukuda S, Cordis G, et al. Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett 2001; 508:369-374.
32. Sethi G, Ahn KS, Chaturvedi MM, et al. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 2007;26:7324-7332.
33. Sethi G, Ahn KS, Sung B, et al. SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkappaBalpha kinase activation. Biochem Pharmacol 2008;76: 1404-1416.